Ira Gore
Hematology & Oncology · Birmingham, ALNPI 1447275565
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,900 and has fallen 98.8% since, to $22 in 2023. That places this record below the midpoint for hematology & oncology clinicians in AL, where the typical reported total is $7,159.
Across 234 payments — averaging $14.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$507
- Novartis$405
- Johnson & Johnson$394
- Takeda Pharmaceuticals U.S.A., Inc.$328
- Amgen$216
- Merck$188
- plus $1K from 25 others
Across 60 payments — averaging $14,227 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$425K
- Merck$233K
- Astrazeneca UK Limited$82K
- Puma Biotechnology, Inc.$59K
- Sanofi US Services Inc.$32K
- AstraZeneca$22K
What the payments were for
- Food & beverage$3,34498%
- Education$642%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 40 | $507 |
| Novartis | 27 | $405 |
| Johnson & Johnson(2 entities) | 36 | $394 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $328 |
| Amgen | 15 | $216 |
| Merck | 14 | $188 |
| AstraZeneca | 10 | $161 |
| Pharmacyclics LLC, An Abbvie Company | 10 | $148 |
| Tesaro, Inc. | 7 | $147 |
| Seagen Inc. | 6 | $98 |
| Genentech USA, Inc. | 5 | $81 |
| Exelixis Inc. | 5 | $79 |
| Lilly USA, LLC | 5 | $75 |
| Bristol Myers Squibb | 4 | $70 |
| Myriad Genetic Laboratories, Inc. | 4 | $60 |
| Eisai Inc. | 4 | $54 |
| Pfizer | 4 | $53 |
| Astellas Pharma US Inc | 3 | $52 |
| Epizyme, Inc. | 3 | $40 |
| Karyopharm Therapeutics Inc. | 2 | $31 |
| Bayer | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 2 | $28 |
| Gilead(2 entities) | 2 | $27 |
| Rigel Pharmaceuticals, Inc. | 1 | $24 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Aurobindo Pharma USA, Inc. | 1 | $17 |
| Dova Pharmaceuticals | 1 | $16 |
| GSK | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Beigene USA, Inc. | 1 | $13 |
| Secura Bio, Inc. | 1 | $12 |
How this compares
$3,408 in reported general payments places this provider in the 35th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Birmingham
- Amitkumar MehtaBirmingham$683K
- Pankit VachhaniBirmingham$545K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Michael BirrerBirmingham$302K
- Rudolph NavariBirmingham$254K
- Mayur NarkhedeBirmingham$193K
- Midhun MallaBirmingham$144K
- Robert ConryBirmingham$143K
- David MooneyBirmingham$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.